^
    Back
    Association details:
    Biomarker:EGFR positive
    Cancer:Lung Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

    Excerpt:
    ...- Must have positive EGFr expression (tumor tissue) by immunohistochemical assay....
    Trial ID:
    NCT01004731
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Klinische Studie für Patienten mit einer fortgeschrittenen Lungenkrebserkrankung mit zwei unterschiedlichen Behandlungsmethoden: Cisplatin oder Carboplatin mit Docetaxel in Kombination mit Cetuximab

    Excerpt:
    ...- histologically or cytologically confirmed NSCLC stadium IV UICC 7 - life expectance more than 3 month - ECOG performance status 0 or 1 - positiv EGFR status (IHC score ≥200)...
    Trial ID:
    2009-016806-18
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Sci Rep
    Title:

    Cetuximab-Polymersome-Mertansine Nanodrug for Potent and Targeted Therapy of EGFR-Positive Cancers

    Published date:
    03/04/2022
    Excerpt:
    Herein, we constructed a robust cetuximab-polymersome-mertansine nanodrug (C-P-DM1) for highly potent and targeted therapy of epidermal growth factor receptor (EGFR)-positive solid tumors. C-P-DM1 with a...6.0-11.3-fold stronger cytotoxicity in EGFR-positive human breast (MDA-MB-231), lung (A549), and liver (SMMC-7721) cancer cells (IC50 = 27.1-135.5 nM) than P-DM1 control.
    DOI:
    10.1021/acs.biomac.1c01065